Bank of America Corp DE Grows Holdings in LivaNova PLC (NASDAQ:LIVN)

Posted by on Jun 6th, 2023

Bank of America Corp DE raised its stake in LivaNova PLC (NASDAQ:LIVN – Get Rating) by 38.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,055,298 shares of the company’s stock after acquiring an additional 293,118 shares during the quarter. Bank of America Corp DE owned approximately 1.97% of LivaNova worth $58,611,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. NorthCrest Asset Manangement LLC boosted its stake in LivaNova by 6.9% in the fourth quarter. NorthCrest Asset Manangement LLC now owns 4,640 shares of the company’s stock valued at $258,000 after acquiring an additional 300 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in LivaNova by 1.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 28,970 shares of the company’s stock valued at $1,810,000 after acquiring an additional 308 shares during the last quarter. Wolverine Asset Management LLC boosted its stake in LivaNova by 35.3% in the third quarter. Wolverine Asset Management LLC now owns 1,454 shares of the company’s stock valued at $73,000 after acquiring an additional 379 shares during the last quarter. Western Pacific Wealth Management LP boosted its stake in LivaNova by 43.2% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,260 shares of the company’s stock valued at $70,000 after acquiring an additional 380 shares during the last quarter. Finally, VELA Investment Management LLC raised its position in shares of LivaNova by 4.4% in the fourth quarter. VELA Investment Management LLC now owns 12,187 shares of the company’s stock valued at $677,000 after purchasing an additional 514 shares during the period. 98.89% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Stock Performance

LivaNova stock opened at $46.34 on Tuesday. The firm’s 50 day simple moving average is $45.66 and its 200 day simple moving average is $50.02. The company has a current ratio of 2.86, a quick ratio of 2.41 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $2.49 billion, a PE ratio of -30.09 and a beta of 0.86. LivaNova PLC has a 1-year low of $40.26 and a 1-year high of $70.57.

LivaNova (NASDAQ:LIVN – Get Rating) last posted its earnings results on Wednesday, May 3rd. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.02. LivaNova had a negative net margin of 7.83% and a positive return on equity of 10.40%. The business had revenue of $263.40 million for the quarter, compared to analyst estimates of $243.43 million. During the same quarter in the prior year, the firm posted $0.48 EPS. LivaNova’s revenue was up 9.7% on a year-over-year basis. As a group, analysts expect that LivaNova PLC will post 2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other LivaNova news, CEO Damien Mcdonald sold 2,220 shares of the business’s stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $42.55, for a total value of $94,461.00. Following the completion of the transaction, the chief executive officer now owns 111,847 shares of the company’s stock, valued at approximately $4,759,089.85. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.19% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $77.00 price target on shares of LivaNova in a research report on Monday, April 17th. Mizuho assumed coverage on shares of LivaNova in a research report on Thursday, April 13th. They issued a “neutral” rating and a $48.00 price target on the stock. StockNews.com assumed coverage on shares of LivaNova in a research report on Thursday, May 18th. They issued a “buy” rating on the stock. Finally, Barclays boosted their price target on shares of LivaNova from $45.00 to $51.00 in a research report on Monday, May 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, LivaNova presently has a consensus rating of “Moderate Buy” and a consensus price target of $64.60.

About LivaNova

(Get Rating)

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiopulmonary and Other segments. The Cardiopulmonary segment is involved in the development, production and sale of cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, and related accessories.

Featured Articles

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.